Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.
Abstract: Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (FGFR) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presence of one or more FGFR mutants from a FGFR mutant gene panel. Kits and primers for identifying the presence of one or more FGFR mutant genes in a biological sample are also disclosed herein.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
July 16, 2024
Assignee:
Janssen Pharmaceutica NV
Inventors:
Suso Jesus Platero, Jayaprakash Karkera
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type:
Grant
Filed:
April 3, 2023
Date of Patent:
July 16, 2024
Assignee:
Mind Medicine, Inc.
Inventors:
Peter Mack, Timm Trenktrog, Dustin Melton, Bethany Amber Doty, Jon Schroeder, Lisa Marie Garrett
Abstract: The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
Type:
Grant
Filed:
October 25, 2019
Date of Patent:
July 9, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Vladimir Simov, William P. Kaplan, John J. Acton, III, Michael J. Ardolino, Joanna L Chen, Peter H. Fuller, Hakan Gunaydin, Derun Li, Ping Liu, Kaitlyn Marie Logan, Joey Methot, Gregori J. Morriello, Santhosh F. Neelamkavil, Luis Torres, Xin Yan, Hua Zhou
Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
July 9, 2024
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Joan Massague, Adrienne Boire, Qing Chen
Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
Type:
Grant
Filed:
May 27, 2020
Date of Patent:
July 9, 2024
Assignee:
Sun Pharmaceutical Industries, Inc.
Inventors:
Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
Abstract: A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of: a compound represented by Formula I: or a pharmaceutically acceptable salt thereof, a compound represented by Formula II: and a compound represented by Formula III: wherein the variables in Formulae I, II and III are as defined in the specification.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
July 2, 2024
Assignee:
The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Abstract: Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.
Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.
Type:
Grant
Filed:
December 17, 2020
Date of Patent:
July 2, 2024
Assignee:
CORVUS PHARMACEUTICALS, INC.
Inventors:
Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian Mccaffery, Andrew Hotson
Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.
Type:
Grant
Filed:
November 11, 2019
Date of Patent:
July 2, 2024
Assignee:
Solventum Intellectual Properties Company
Inventors:
George W. Griesgraber, Bryon A. Merrill, Michael J. Rice
Abstract: The invention relates to compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering such a compound.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
June 25, 2024
Assignee:
Novartis AG
Inventors:
Joseph Michael Young, Michael Robert Turner, Peichao Lu
Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
Abstract: A process for producing a vegan cannabinoid chewy wherein the process entails mixing a cannabinoid compound with a sugar solution, pectin mixture, and agar mixture.
Abstract: The present invention relates to the technical field of natural medicines, and in particular to a triterpenoid compound with an effect of improving glucose and lipid metabolism disorders, and preparation and application thereof. A novel triterpenoid compound was obtained by separation from Momordica charantia L. for the first time in the present invention. Studies on a mouse primary hepatocyte model and a 3T3-L1 preadipocyte model show that the novel triterpenoid compound in the present invention has activity of regulating glucose and lipid metabolism, and after combination with known triterpenoid compound Momordicoside G, the activity of regulating glucose and lipid metabolism is significantly higher than that of a single compound at the same dose, indicating that the novel triterpenoid compound and a complex thereof in the present invention can be used to improve glucose and lipid metabolism disorders and provide a new way for diabetes treatment.
Type:
Grant
Filed:
July 1, 2022
Date of Patent:
June 11, 2024
Assignee:
SERICULTURAL & AGRI-FOOD RESEARCH INSTITUTE GUANGDONG ACADEMY OF AGRICULTERAL SCIENCES
Abstract: Compositions and methods are presented that, upon administration prior to trauma, are effective to prevent and/or reduce severity of sequelae of TBI upon trauma. Advantageously, the compositions presented herein can be orally administered, have an excellent safety profile, and will not require a prescription by physician or hospital admission.
Abstract: The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine rings without using palladium, a strong base, or a high-temperature reaction. In particular, they successfully developed a method that can be used to synthesize iminium salts as intermediates, synthesize cyano compounds from these iminium salts, and cyclize the cyano compounds into pyridines under very mild reaction conditions.